A recent study reported that activation of the JAK/STAT signaling pathway leads to the development of resistance to BRAF inhibitors in BRAFV600E thyroid carcinoma, which makes the JAK/STAT pathway a potential target for antitumor activity and to overcome drug resistance [82]. Here, BRAF is linked to thyroid gland carcinoma.